<DOC>
	<DOCNO>NCT01579812</DOCNO>
	<brief_summary>The primary objective study determine metformin administer combination chemotherapy woman advance ovarian , primary peritoneal fallopian tube cancer improve recurrence-free survival 18 month compare control .</brief_summary>
	<brief_title>Evaluation Metformin , Targeting Cancer Stem Cells Prevention Relapse Gynecologic Patients</brief_title>
	<detailed_description>Despite 70 % remission rate surgery chemotherapy , majority patient stage III/IV ovarian cancer relapse die disease . This consistent cancer stem cell ( CSC ) model residual treatment resistant stem cell persist initiate disease recurrence . Laboratory study indicate therapy target CSC greatly improve cancer outcomes . We recently characterize population CSC ovarian cancer . Importantly , similar observe breast cancer , find diabetes drug metformin restrict ovarian CSC growth proliferation . In addition metformin increase tumor cell sensitivity chemotherapy . Consistent , epidemiologic study demonstrate diabetic patient ovarian cancer take metformin well outcomes take metformin . However , metformin test anti-cancer stem cell agent ovarian cancer . Thus propose perform phase II clinical trial use metformin anti-cancer stem cell agent ovarian cancer patient . Patients plan receive primary surgical debulking initiate metformin therapy prior surgery continue surgery along chemotherapy . Patients treat neoadjuvantly initiate metformin chemotherapy prior surgery continue metformin chemotherapy surgery . Tumor specimen acquire patient time primary surgery . The primary objective study determine metformin improve recurrence-free survival ( RFS ) patient relative historical control . Secondary objective study : ( ) compare amount CSC primary tumor specimen metformin treat patient versus match control tumor bank , ( b ) determine metformin improve overall survival relative historical control , ( c ) confirm safety metformin non-diabetic ovarian cancer patient , ( ) laboratory study indicate metformin active p53 mutant cell p53 mutate ~50 % ovarian cancer , ass whether response rate correlate p53 mutation status . If successful , well tolerated FDA approve drug could immediately translate phase III trial impact patient outcome .</detailed_description>
	<mesh_term>Peritoneal Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>1 . Patients potential diagnosis ovarian , fallopian , primary peritoneal cancer . 2 . Care plan include surgical debulking traditional adjuvant neoadjuvant chemotherapy ( 69 cycle platinum taxane base therapy ) . 3 . Eastern Cooperative Oncology Group performance status 02 . 4 . Age &gt; 18 year &lt; 80 year . 5 . Adequate renal function ( serum creatinine &lt; 1.4mg/dL ) . 6 . Adequate liver function ( bilirubin &lt; 1.5 time ULN ) . Alanine Aminotransferase ( ALT ) Aspartate Aminotransferase ( AST ) &lt; 5 time upper limit normal case liver metastasis . ALT AST &lt; 2.5 time ULN absence liver metastasis . 7 . Ability understand complete write informed consent . 8 . Mentally , physically , geographically able undergo treatment follow . 1 . Patients diabetes mellitus . ( Patients history gestational diabetes allow include study . ) 2 . Metformin use last 6 month . 3 . A known hypersensitivity metformin . 4 . A history metabolic acidosis , include ketoacidosis increase risk lactic acidosis . 5 . Pregnancy Lactation . 6 . Patients severe and/or uncontrolled medical condition . 7 . Patients history renal disease . 8 . Patients know active malignancy ( exclude adequately treat basal cell / squamous cell skin cancer , situ cancer , cancer patient disease free 2 year ) . 9 . Patients receive investigational agent .</criteria>
	<gender>Female</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Ovarian , Fallopian Tube , Primary Peritoneal Cancer</keyword>
</DOC>